Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
Sentiment Analysis
The approval makes Wegovy the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states. It follows a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use in May 2026.
The latest decision marks the fifth regulatory approval for the Wegovy pill after previous authorizations in the United States, the U.K. , the United Arab Emirates, and Bahrain. The European Commission also approved the Wegovy 7.2 mg injection in a single-dose pen for obesity. Novo Nordisk said it plans to introduce the treatment in additional countries during the second half of 2026.
Source: Benzinga
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.